These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32519774)

  • 1. Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer.
    Ikesue H; Kusuda K; Satsuma Y; Nishiwaki F; Miura R; Masuda Y; Hirabatake M; Muroi N; Fujimoto D; Morimoto T; Tomii K; Hashida T
    J Clin Pharm Ther; 2020 Dec; 45(6):1288-1294. PubMed ID: 32519774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pharmacist-managed immune checkpoint inhibitor toxicities.
    Le S; Chang B; Pham A; Chan A
    J Oncol Pharm Pract; 2021 Apr; 27(3):596-600. PubMed ID: 32507100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of protocol-based pharmacotherapy management on anticoagulation with warfarin for patients with cardiovascular surgery.
    Katada Y; Nakagawa S; Minakata K; Odaka M; Taue H; Sato Y; Yonezawa A; Kayano Y; Yano I; Nakatsu T; Sakamoto K; Uehara K; Sakaguchi H; Yamazaki K; Minatoya K; Sakata R; Matsubara K
    J Clin Pharm Ther; 2017 Oct; 42(5):591-597. PubMed ID: 28503837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of protocol-based pharmacotherapy management collaboration between hospital and community pharmacists to address capecitabine-related hand-foot syndrome in cancer patients: a retrospective study.
    Nakamura N; Shiraiwa H; Haruna Y; Ichijima T; Takeda T; Hasegawa K; Kusumoto M; Yano Y
    J Pharm Health Care Sci; 2021 Mar; 7(1):8. PubMed ID: 33641672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Keiser MF; Patel AB; Altan M
    Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Introduction of PBPM and Its Effects for a Home Care Support Clinic].
    Imajo H; Ogawa R; Oka T; Hasegawa S; Hirata E; Kishimoto M; Yasukawa K; Hirohara M; Kushida K
    Gan To Kagaku Ryoho; 2018 Mar; 45(Suppl 1):35-37. PubMed ID: 29650869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of physician-pharmacist collaborative protocol-based pharmacotherapy management for HIV outpatients: a retrospective cohort study.
    Urano K; Ishibashi M; Matsumoto T; Ohishi K; Muraki Y; Iwamoto T; Kunimasa J; Okuda M
    J Pharm Health Care Sci; 2020; 6():9. PubMed ID: 32377369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
    Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
    Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty.
    Hanson RL; Gannon MJ; Khamo N; Sodhi M; Orr AM; Stubbings J
    J Manag Care Pharm; 2013; 19(1):49-67. PubMed ID: 23383700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
    Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities.
    Renna CE; Dow EN; Bergsbaken JJ; Leal TA
    J Oncol Pharm Pract; 2019 Jun; 25(4):954-960. PubMed ID: 30975067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of Introducing PBPM for Outpatient Cancer Drug Therapy and Its Impact on Physician Workload].
    Yanagawa T; Kataoka K; Yamashita N; Yanai M; Tanaka K; Bando J; Fukuda T; Miyazaki M; Ogata F; Hirayama M; Tanaka A; Hirata M; Demachi T; Ikeda M; Kimura T
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):747-751. PubMed ID: 39191693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pharmacist-led intervention protocol on preventing postoperative delirium after elective cardiovascular surgery.
    Asai Y; Yanagawa T; Takahashi M
    PLoS One; 2023; 18(10):e0292786. PubMed ID: 37824500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors.
    Saito Y; Uchiyama K; Sakamoto T; Yamazaki K; Kubota K; Takekuma Y; Komatsu Y; Sugawara M
    Biol Pharm Bull; 2020; 43(12):1969-1974. PubMed ID: 33268718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
    Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
    J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.